American Association for Cancer Research Annual Meeting门票

The American Association for Cancer Research (AACR) Annual Meeting is one of the world’s largest and most influential oncology conferences, drawing more than 20,000 attendees each year. This year’s meeting showcased cutting-edge cancer science and medicine, attracting cancer researchers from across the globe as well as representatives from numerous pharmaceutical companies. AACR is committed to advancing the integration and development of basic research, translational science, and clinical appli

The Exhibition Value of the American Association for Cancer Research Annual Meeting

• The AACR Annual Meeting is the world’s largest and most authoritative academic event in cancer research. Since its inception in 1907, it has been held over a hundred times and is widely recognized in the industry as a leading indicator of global trends in cancer research and a central hub for oncology drug development. Hosted by the American Association for Cancer Research, the conference rotates annually among major U.S. cities. The 2026 meeting will take place from April 17 to 22 at the San Diego Convention Center in California, expected to attract tens of thousands of scientists, clinicians, and industry representatives from dozens of countries and regions worldwide. It serves as a vital platform for advancing the field of anti‑cancer research, offering a comprehensive showcase of cutting‑edge scientific and medical breakthroughs.
• The core value of exhibiting lies in its unparalleled academic authority and its role as a platform that precisely connects global resources for oncology R&D. The AACR Annual Meeting stands as the premier forum for scholarly exchange and the dissemination of research findings in the global cancer research community, bringing together top scientists, clinical investigators, and industry leaders from around the world each year. The program features a wide array of specialized forums and sessions, including plenary talks, thematic symposia, educational courses, and poster presentations, covering all aspects of basic science, translational medicine, clinical research, and preventive medicine. The 2026 conference will feature numerous high‑impact academic presentations on前沿 topics such as AI‑driven cancer research, mechanisms of early‑onset cancers, and innovative therapeutic approaches.
• The exhibition provides an academic exchange and commercial collaboration platform that spans the entire oncology R&D value chain. Exhibits encompass a full spectrum of products, including targeted cancer therapies, immunotherapies, antibody‑drug conjugates (ADCs), cell therapies, gene editing tools, companion diagnostics, biomarkers, experimental models, and research equipment. From fundamental scientific discoveries to clinical translation, and from early‑stage drug development to commercialization, the event fosters a complete industrial ecosystem. The 2026 conference includes educational sessions, methodological workshops, plenary discussions, and poster presentations, offering researchers, clinicians, and pharmaceutical companies a multidimensional platform for knowledge sharing.
• The exhibition aligns with three major industry trends—precision medicine, immunotherapy, and AI empowerment—establishing a technological hub where academia, industry, and clinical practice converge deeply. The 2026 conference will feature several high‑profile plenary sessions, including the opening address titled “Precision, Collaboration, Mission: Advancing Global Cancer Science to Save Lives,” as well as thematic sessions on AI‑driven cancer research, mechanisms of early‑onset cancers, and innovative treatment modalities. In addition, the program will include cutting‑edge educational courses covering CRISPR screening, protein degradation technologies, spatial omics, and other前沿 areas. By showcasing the complete innovation pipeline—from early discovery to clinical application—the conference serves as a critical window for observing and tracking global trends in cancer research.
• For Chinese enterprises, this exhibition represents a strategic gateway for expanding into global markets, connecting with international resources, and demonstrating their innovative capabilities. The 2026 AACR Annual Meeting will see active participation from numerous Chinese pharmaceutical companies. Cornerstone Pharmaceuticals has had three of its independently developed ADC candidates selected for poster presentations, including EGFR/HER3 bispecific ADCs and SSTR2/DLL3 bispecific ADCs; Asymchem has four preclinical studies chosen, focusing on innovative drugs such as orebatinib and APG‑2449. Through this internationally prestigious academic platform, Chinese companies can showcase the forefront of China’s pharmaceutical innovation, enhance their global visibility, and forge connections with worldwide research and commercial networks.